Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 12, 2020
Daily News
November 12, 2020
- AstraZeneca Launches Healthcare Innovation Hub in Japan
November 12, 2020
- No Consensus on Flu Vaccines’ Efficacy against COVID-19: NIID Chief
November 12, 2020
- Japan to Give Ultracold Chain-Required COVID-19 Shots to Certain People in Short Period: Minister
November 12, 2020
- Lower House Health Committee Starts Debate on Immunization Bill; Minister Says to Publish PAFSC Meeting Minutes ASAP
November 12, 2020
- Chuikyo’s Drug Pricing Subcommittee to Meet after 4-Month Hiatus to Discuss Off-Year Re-Pricing, Hear Industry Views
November 12, 2020
- Chuikyo Payer Rep Calls for Cost-Effectiveness Assessment of Drugs Used Together with Medical Devices
November 12, 2020
- Japan’s 1st Therapeutic App OK’ed for Health Coverage, Due for Release on Dec. 1
November 12, 2020
- Nippon Kayaku’s Biosimilar Sales to Hit 10 Billion Yen Mark in Full-Year, Trastuzumab Upbeat
November 12, 2020
- Roche Diagnostics Rolls Out COVID-19 Antibody Detection Reagent in Japan for Research Use
November 12, 2020
- New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
November 12, 2020
- Medicago’s COVID-19 Vaccine Shows Positive PI Results, Now Gearing Up for PII, PIII Studies
November 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…